Trial Profile
A Comparison of Immediate Changes in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Poractant alfa (Primary)
- Indications Neonatal respiratory distress syndrome
- Focus Therapeutic Use
- 05 Jun 2017 According to Cornerstone Pharmaceuticals media release, Cornerstone Pharmaceuticals changed name to Rafael Pharmaceuticals
- 10 Apr 2015 New trial record